SAN DIEGO, May 14, 2024 (Globe Newswire) — Viracta Therapeutics, Inc., a clinical-stage precision oncology company focused on treating and preventing virus-related cancers affecting patients around the world. (NASDAQ: VIRX) today appointed Michael Firm as Chief Financial Officer, effective immediately. Mr. Faerm is a veteran biotechnology executive with more than 25 years of experience in life science companies, equity research, and investment banking.
“We are thrilled to welcome Mike, a Wall Street veteran in the life sciences industry, who we believe will support our next phase of development,” said Mark Rosella, president and chief executive officer of Viracta. I'm happy about that,” he said. “The promising clinical data generated to date highlights the innovative potential of Nanaval. “Kick and Kill” Approaches to effectively address the unmet treatment needs of patients with EBV-associated cancers. We look forward to leveraging Mike's strategic, operational, and financial leadership as we move forward with Nana-val's late development and toward several important milestones. . ”
Faerm added: “I am thrilled to be joining Viracta at this exciting time and am relishing the opportunity to meaningfully impact the future of the company. I look forward to advancing the company's mission to bring innovative treatments to patients with virus-related cancers.”
Mr. Faerm most recently served as Interim Chief Financial Officer of Harpoon Therapeutics, Inc., which was acquired by Merck & Co. for approximately $680 million, where he helped lead a $150 million PIPE financing. Prior to joining Harpoon, Mr. Faerm served as Chief Financial Officer of Artiva Biotherapeutics, Inc., where he directed financial strategy and operations and oversaw the company's investor relations, financial planning, accounting and facilities functions. was doing. Mr. Faerm previously served as consulting and interim chief financial officer and chief business officer for numerous biopharmaceutical companies. Prior to that, Mr. Faerm served as Chief Business Officer at Innoviva, Inc. (formerly Theravance, Inc.), and prior to that he served in business development and strategic finance roles at Forest Laboratories and Regeneron Pharmaceuticals. I was there. Mr. Firm's Wall Street experience includes stints as a senior equity research analyst covering the pharmaceutical sector at Credit Suisse and Wells Fargo Securities, and as an investment banker at Merrill Lynch, where he held a wide range of strategic positions in biopharmaceuticals and pharmaceuticals. and having executed capital market transactions. other healthcare fields. Mr. Faerm received his MBA from Harvard's School of Business, his master's degree in civil engineering from Stanford University, and his bachelor's degree in civil engineering from Columbia University.
About Viracta Therapeutics, Inc.
Viracta is a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers affecting patients around the world. Viracta's lead product candidate is an all-oral combination therapy of the company's proprietary investigational drug nanatinostat and the antiviral drug valganciclovir (collectively known as Nanaval). Nana-val currently has multiple subtypes of relapsed or refractory (R/R) Epstein-Barr virus positive (EBV+) Multinational, open-label, phase 1b/2 clinical trial for the treatment of patients with lymphoma (NAVAL-1) and recurrent or metastatic (R/M) EBV+ Nasopharyngeal carcinoma (NPC) and other advanced EBV+ Solid tumor. Viracta is also pursuing the application of its “.kick and killApproaches in other EBV-related diseases.
For more information, please visit www.viracta.com.
Forward-looking statements
This document contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding: the ability of Viracta's product candidates to effectively address the unmet therapeutic needs of patients with EBV-related cancers, the details, timeline and expected progress of Viracta's ongoing and anticipated clinical trials; Updates thereon, announced changes in management, statements relating to or suggesting Viracta's future performance, goals and potential, and management's ability to contribute to the execution of Viracta's vision, performance, goals and potential; To do. Risks and uncertainties related to Viracta that could cause actual results to differ materially from those expressed or implied by forward-looking statements include, but are not limited to: Not limited. Viracta plans to develop and commercialize product candidates, including all oral combinations of nanatinostat and valganciclovir. the timing of Viracta's planned initiation of clinical trials; the timing of data availability from Viracta's clinical trials; Previous preclinical and clinical results may not predict future clinical results. the timing of planned investigational new drug applications or new drug applications; Viracta's plans to research, develop and commercialize its current and future product candidates; the clinical utility, potential benefits and market acceptance of Viracta's product candidates; Viracta's ability to manufacture or supply nanatinostat, valganciclovir, and pembrolizumab for clinical trials; Viracta's estimates of its ability to finance its ongoing operations through 2025, future expenses, capital requirements and future need for additional financing;
If any of these risks materialize, or if the underlying assumptions prove incorrect, actual results could differ materially from those suggested by these forward-looking statements. Additional risks and uncertainties that could cause actual outcomes or results to differ materially from those contemplated in the forward-looking statements are described under the caption “Risk Factors” and in the documents submitted by Viracta. or elsewhere in Viracta's reports or other documents that you intend to submit. Published by the SEC from time to time and available at www.sec.gov.
The forward-looking statements contained in this communication are made only as of the date of this communication. Viracta undertakes no obligation, and does not intend to update these forward-looking statements, except as required by law or applicable regulation.
Investor Information Contact:
ashley barrett
Head of Investor Relations and Corporate Communications
Viracta Therapeutics
abarreto@viracta.com
SOURCE Viracta Therapeutics, Inc.
